BRPI0518781A2 - formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto - Google Patents

formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto

Info

Publication number
BRPI0518781A2
BRPI0518781A2 BRPI0518781-8A BRPI0518781A BRPI0518781A2 BR PI0518781 A2 BRPI0518781 A2 BR PI0518781A2 BR PI0518781 A BRPI0518781 A BR PI0518781A BR PI0518781 A2 BRPI0518781 A2 BR PI0518781A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
compound
preparing
prophylaxis
treatment
Prior art date
Application number
BRPI0518781-8A
Other languages
English (en)
Inventor
Nazaneen Pourkavoos
James R Ney
Maria T Cruanes
Yunhui Wu
Saurabh A Palkar
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518781(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0518781A2 publication Critical patent/BRPI0518781A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇçO FARMACÊUTICA, PROCESSO PARA PREPARAR UMA FORMULAÇçO FARMACÊUTICA, E, USO DE UM COMPOSTO. São descritas formulações farmacêuticas adequadas para administração oral em formas de dosagem sólidas. As composições compreendem uma quantidade eficaz de um sal básico de um composto de fórmula (I) e uma composição que controla a taxa de liberação compreendendo um agente solubilizante, um agente geleificante e uma carga solúvel em água; em que R¹, R², R² e R^ 4^ são definidos aqui. As formulações são adequadas para uso na inibição da HIV integrase, no tratamento e profilaxia de infecção por HIV e no tratamento, profilaxia e atraso no início de ação da AJDS
BRPI0518781-8A 2004-12-03 2005-12-02 formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto BRPI0518781A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63294404P 2004-12-03 2004-12-03
PCT/US2005/043727 WO2006060711A2 (en) 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition

Publications (1)

Publication Number Publication Date
BRPI0518781A2 true BRPI0518781A2 (pt) 2008-12-09

Family

ID=36118082

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518781-8A BRPI0518781A2 (pt) 2004-12-03 2005-12-02 formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto

Country Status (16)

Country Link
US (1) US8852632B2 (pt)
EP (2) EP1904067B2 (pt)
JP (1) JP5228488B2 (pt)
KR (1) KR101351059B1 (pt)
CN (1) CN101068550B (pt)
AU (1) AU2005311652B2 (pt)
BR (1) BRPI0518781A2 (pt)
CA (1) CA2588445C (pt)
ES (1) ES2755273T3 (pt)
IL (1) IL183615A (pt)
MX (1) MX2007006635A (pt)
NO (1) NO20073405L (pt)
NZ (1) NZ555120A (pt)
RU (1) RU2382648C2 (pt)
WO (1) WO2006060711A2 (pt)
ZA (1) ZA200703866B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101068533B (zh) * 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
JP2008521934A (ja) * 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用
WO2009009531A2 (en) 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
CA2777937C (en) * 2009-10-26 2017-08-29 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
US8987272B2 (en) * 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US9968607B2 (en) * 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2529741B1 (en) * 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
US20150224086A1 (en) * 2012-08-23 2015-08-13 Hetero Research Foundation Pharmaceutical Formulations of Rufinamide
US9763934B2 (en) * 2014-03-05 2017-09-19 Professional Compounding Centers Of America Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
US20210290548A1 (en) * 2018-06-06 2021-09-23 Merck Sharp & Dohme Corp. Formulations of raltegravir

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
CA2393344C (en) * 1999-12-03 2009-09-01 Polichem S.A. Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
JP4101661B2 (ja) * 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
MXPA04003932A (es) 2001-10-26 2004-06-18 Angeletti P Ist Richerche Bio Inhibidores de la hidroxipirimidinona carboxamida n-sustituida de la integrasa del virus de inmunodeficiencia humana.
WO2003035076A1 (en) 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2003220186A1 (en) * 2002-04-10 2003-10-27 Merck And Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
EP1578748B1 (en) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
JP2007517015A (ja) 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
CN101068533B (zh) 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物
JP2008521934A (ja) 2004-12-03 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази

Also Published As

Publication number Publication date
US20070292504A1 (en) 2007-12-20
MX2007006635A (es) 2007-06-19
JP5228488B2 (ja) 2013-07-03
NO20073405L (no) 2007-07-02
RU2007125122A (ru) 2009-01-10
EP2586444B1 (en) 2019-09-25
EP1904067B1 (en) 2013-11-20
CN101068550B (zh) 2011-03-30
EP1904067A2 (en) 2008-04-02
NZ555120A (en) 2009-11-27
IL183615A (en) 2013-01-31
IL183615A0 (en) 2007-10-31
ZA200703866B (en) 2008-03-26
CA2588445A1 (en) 2006-06-08
WO2006060711A3 (en) 2006-09-08
EP1904067B2 (en) 2017-10-11
EP2586444A1 (en) 2013-05-01
WO2006060711A2 (en) 2006-06-08
CA2588445C (en) 2013-06-25
RU2382648C2 (ru) 2010-02-27
JP2008521932A (ja) 2008-06-26
US8852632B2 (en) 2014-10-07
AU2005311652A1 (en) 2006-06-08
KR101351059B1 (ko) 2014-02-17
ES2755273T3 (es) 2020-04-22
AU2005311652B2 (en) 2010-12-02
CN101068550A (zh) 2007-11-07
KR20070085695A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
BRPI0518781A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BR0213522B8 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BR0116299A (pt) Composto, composição farmacêutica, método para o tratamento ou profilaxia de uma infecção picornaviral em um mamìfero, e, uso de um composto
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
WO2005086700A3 (en) Hiv integrase inhibitors
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
TW200517106A (en) Sustained release pharmaceutical compositions
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
SE9901573D0 (sv) New compounds
AR106699A2 (es) Compuestos farmacéuticamente activos, su manufactura, composiciones que los contienen y su uso
MX2022016263A (es) Derivados de ciclobutil-urea.
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BRPI0411702A (pt) uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
BRPI0519248A2 (pt) formulaÇço oral de liberaÇço imediata de um composto ativo, e, mÉtodo para a preparaÇço de uma formulaÇço

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.